ATE201828T1 - Verwendung eines cgrp antagonisten zur behandlung von flechten und pruritus und so erhaltene zubereitung - Google Patents

Verwendung eines cgrp antagonisten zur behandlung von flechten und pruritus und so erhaltene zubereitung

Info

Publication number
ATE201828T1
ATE201828T1 AT96400456T AT96400456T ATE201828T1 AT E201828 T1 ATE201828 T1 AT E201828T1 AT 96400456 T AT96400456 T AT 96400456T AT 96400456 T AT96400456 T AT 96400456T AT E201828 T1 ATE201828 T1 AT E201828T1
Authority
AT
Austria
Prior art keywords
lichen
pruritus
preparation
treatment
cgrp antagonist
Prior art date
Application number
AT96400456T
Other languages
English (en)
Inventor
Lacharriere Olivier De
Lionel Breton
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9477497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE201828(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oreal filed Critical Oreal
Application granted granted Critical
Publication of ATE201828T1 publication Critical patent/ATE201828T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT96400456T 1995-03-28 1996-03-04 Verwendung eines cgrp antagonisten zur behandlung von flechten und pruritus und so erhaltene zubereitung ATE201828T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9503627A FR2732220B1 (fr) 1995-03-28 1995-03-28 Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue

Publications (1)

Publication Number Publication Date
ATE201828T1 true ATE201828T1 (de) 2001-06-15

Family

ID=9477497

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96400456T ATE201828T1 (de) 1995-03-28 1996-03-04 Verwendung eines cgrp antagonisten zur behandlung von flechten und pruritus und so erhaltene zubereitung

Country Status (14)

Country Link
US (1) US5935586A (de)
EP (1) EP0734728B2 (de)
JP (1) JP3043610B2 (de)
AR (1) AR001435A1 (de)
AT (1) ATE201828T1 (de)
BR (1) BR9601467A (de)
CA (1) CA2172778C (de)
DE (1) DE69613168T3 (de)
ES (1) ES2159697T5 (de)
FR (1) FR2732220B1 (de)
HU (1) HUP9600764A3 (de)
MX (1) MX9601151A (de)
PL (1) PL313511A1 (de)
RU (1) RU2152785C1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
JP2001233764A (ja) * 2000-02-22 2001-08-28 Hisamitsu Pharmaceut Co Inc Ｎ−置換−ｏ−トルイジン誘導体からなる鎮痒剤
US11517612B2 (en) 2016-11-18 2022-12-06 Nepsone Ehf Methods of treating inflammatory skin disorders
DK1556020T3 (da) 2002-08-12 2009-06-22 Birkir Sveinsson Anvendelse af CGRP-antagonistforbindelser til behandling af psoriasis
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
SI3045182T1 (en) 2005-11-14 2018-08-31 Teva Pharmaceuticals International Gmbh An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
EP2265287B1 (de) 2008-03-04 2018-09-05 Teva Pharmaceuticals International GmbH Verfahren zur behandlung von chronischen schmerzen
WO2011024113A1 (en) 2009-08-28 2011-03-03 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
HUE065397T2 (hu) 2014-03-21 2024-06-28 Teva Pharmaceuticals Int Gmbh Kalcitonin génekkel kapcsolatos peptid elleni antagonista antitestek és azokat alkalmazó eljárások
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9201425D0 (sv) * 1992-05-06 1992-05-06 Kabi Pharmacia Ab Method and means for preventing constriction of the pupil in the eye
JP2656700B2 (ja) * 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
US5445823A (en) * 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith

Also Published As

Publication number Publication date
EP0734728B1 (de) 2001-06-06
FR2732220A1 (fr) 1996-10-04
BR9601467A (pt) 1998-03-31
RU2152785C1 (ru) 2000-07-20
EP0734728B2 (de) 2008-02-13
DE69613168T2 (de) 2001-09-27
EP0734728A1 (de) 1996-10-02
CA2172778A1 (fr) 1996-09-29
AR001435A1 (es) 1997-10-22
PL313511A1 (en) 1996-09-30
HU9600764D0 (en) 1996-05-28
HUP9600764A3 (en) 1998-03-02
ES2159697T5 (es) 2008-07-01
JP3043610B2 (ja) 2000-05-22
MX9601151A (es) 1997-02-28
ES2159697T3 (es) 2001-10-16
FR2732220B1 (fr) 1997-04-25
HUP9600764A2 (en) 1997-06-30
CA2172778C (fr) 2008-02-12
DE69613168T3 (de) 2009-03-05
JPH08268904A (ja) 1996-10-15
DE69613168D1 (de) 2001-07-12
US5935586A (en) 1999-08-10

Similar Documents

Publication Publication Date Title
DE69600399D1 (de) Verwendung von einem CGRP Antagonist für dir Behandlung von Hauterythemen neurogenischen Ursprung und erhaltene Zubearbeitung
DE69622074D1 (de) Cystin-Silikon-Copolymere und deren Verwendung zur Behandlung von keratinischen Materialien
DE69830728D1 (de) Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
ATE331522T1 (de) Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum
ATE256463T1 (de) Pharmazeutische zubereitung zur verwendung in der behandlung von diabetes
NO962179L (no) Fremgangsmåte for fremstilling av metallocen og anvendelse derav
DE69720463D1 (de) Sulfonamid-derivate und ihre verwendung zur behandlung von zns-erkrankungen
EP1027016A4 (de) Verfahren und pharmazeutische zusammensetzungen zum verschluss von metzhautrissen
FI974323L (fi) Selektiivisiä NMDA-antagonisteja sisältäviä yhdistelmiä parkinsonismin hoitoa varten
DE69115921D1 (de) Verfahren zur behandlung und verwendung von abfallstoffen
ATA11989A (de) Mittel zur vorbeugung gegen und behandlung von parodontopathien
DE3780972D1 (de) Verwendung von spezifischen n-methyl-d-aspartat-rezeptor-antagonisten zur praevention und behandlung von neurodegeneration.
ATE201828T1 (de) Verwendung eines cgrp antagonisten zur behandlung von flechten und pruritus und so erhaltene zubereitung
DE69635708D1 (de) Tetrandrin zur behandlung von augenentzündungen
FI972245A7 (fi) Meso-monojodisubstituoidut tetramakrosykliset yhdisteet sekä niiden valmistus- ja käyttömenetelmät
ATE227278T1 (de) Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression
DE69306915D1 (de) Kombination zur Detektion von Weichgewebeanomalien
DE69432595D1 (de) Antagonisten des angiotensin ii-rezeptors zur behandlung von chronischen entzündlichen erkrankungen
FI973254A7 (fi) Menetelmä aminoetyylietanoliamiinin ja/tai hydroksietyylipiperatsiinin valmistamiseksi
FI952458L (fi) Dimetyylibentsofuraanien ja dimetyylibentsopyraanien käyttö 5-HT3-antagonisteina
DE69635977D1 (de) Verfahren zur Bestimmung der therapeutischen Wirkung von Metalloproteinase-Verbindungen, neue Inhibitor-Verbindungen und deren therapeutische Verwendung
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
DE69614739D1 (de) Pflaster zur Behandlung von Pflanzen
FI971127L (fi) 2,4-diaminopyrimidiini-3-oksidin tai jonkin sen suolan käyttö kollageenin kypsymis- ja rakentumishäiriöiden hoitamiseen
KR960702749A (ko) 심장혈관 질환의 치료를 위한 천연물 및 이와 관련된 합성 화합물의 사용(Use of Natural Products and Related Synthetic Compounds for the Treatment of Cardiovascular Disease)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties